Claims for Patent: 4,292,305

Summary for Patent: 4,292,305

Title:	Antiallergic imidodisulfamides
Abstract:	Imidodisulfamide derivatives useful in the treatment of allergic conditions are prepared by reaction of an appropriately substituted primary amine and bis(chlorosulfonyl) imide in the presence of a tertiary amine.
Inventor(s):	Ali; Fadia E. (Cherry Hill, NJ), Krell; Robert D. (Medford, NJ), Snader; Kenneth M. (Hatboro, PA)
Assignee:	SmithKline Corporation (Philadelphia, PA)
Application Number:	06/121,066
Patent Claims:	1. A compound represented by the formula: ##STR5## wherein: A is a single valence bond, an alkylene chain --(CH.sub.2).sub.n -- in which n is a positive integer 2, 3, 4 or 6, a branched alkylene chain of from 2 to 4 carbon atoms, or phenylmethylene; R.sub.1 is hydrogen, 3- or 4-bromo, 3- or 4-chloro, or 3- or 4-trifluoromethyl; and R.sub.2 is hydrogen, with the proviso that when n is 2, R.sub.1 is 4-chloro, 4-bromo, 4-methoxy or 3-trifluoromethyl and R.sub.2 is hydrogen or together with R.sub.1 in adjacent positions forms either a 3,4-dichloro substitution or a fused benzo ring, and further with the proviso that when A is a single valence bond R.sub.1 is not hydrogen or 4-chloro, or an alkali metal salt of said compound. 2. A compound according to claim 1 in which A is an alkylene chain, R.sub.1 is hydrogen, 3-bromo, 3-chloro or 4-chloro, and R.sub.2 is hydrogen. 3. A compound according to claim 2 being the compound 1,5-di-(4-chlorophenethyl)-imidodisulfamide. 4. A compound according to claim 2 being the compound 1,5-di-(4-phenylbutyl)-imidodisulfamide. 5. A compound according to claim 1 in which A is a single valence bond. 6. A compound according to claim 5 being the compound 1,5-di-(4-bromophenyl)-imidodisulfamide. 7. A pharmaceutical composition for inhibiting the symptoms of asthma comprising a nontoxic pharmaceutical carrier or diluent and an amount sufficient to produce said inhibition of a compound of claim 1. 8. A pharmaceutical composition according to claim 7 in a form suitable for administration by inhalation. 9. A pharmaceutical composition according to claim 7 comprising a solution or suspension of the active ingredient in sterile water. 10. A pharmaceutical composition according to claim 7 in the form of an aerosol formulation. 11. A pharmaceutical composition according to claim 7 in which the pharmaceutical carrier or diluent is a solid. 12. A method of inhibiting the symptoms of asthma which comprises administering to an animal or human subject in need of said inhibition a therapeutically effective amount for producing said inhibition of a compound of claim 1. 13. The method according to claim 12 in which the active ingredient is administered in a daily dosage regimen of from about 0.5 mg. to about 2000 mg. 14. A method of antagonizing the effects of SRS-A on bronchial smooth muscle which comprises administering to an animal or human subject in need of said antagonism an amount sufficient to product said antagonism of a compound of claim 1.

Details for Patent 4,292,305

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23